3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Other solid neoplasm
2
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Interventions
pembrolizumab
2
atezolizumab
2
Nivolumab
2
entinostat
1
durvalumab
1
cemiplimab
1
bemcentinib
1
avelumab
1
Polymerase Chain Reaction
1
Microarray Analysis
1
Levoleucovorin
1
Leucovorin
1
Ipilimumab
1
Interleukin-2
1
In Situ Hybridization, Fluorescence
1
Immunoglobulin G
1
Immunoenzyme Techniques
1
Immune Checkpoint Inhibitors
1
Gene Expression Profiling
1
Flow Cytometry
1
Fentanyl
1
Etoposide
1
Docetaxel
1
Disulfides
1
Cyclophosphamide
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
bemcentinib
×
Dermatologic
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts